LXRX's Business Model
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.lexpharma.com |
| CEO (Chief Executive Officer) | Michael S. Exton |
| Number of Employees | |
| IPO date | April 7, 2000 |
LXRX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 2445 Technology Forest Boulevard |
| City | The Woodlands |
| State | TX |
| Phone | 281 863 3000 |
| Zip Code | 77381 |
| Other Identifiers | |
| CIK | 0001062822 |
| ISIN | US5288723027 |
| CUSIP | 528872302 |
| Open | 1.12 |
| Previous Close | 1.13 |
| Volume | 3.23 Mil. |
| Average Volume | 4.98 Mil. |
| Day’s Range | 1.055 – 1.13 |
| 52 Week Range | 0.28-2.45 |
| MA (50) | 0.7382 |
| MA (200) | 0.86545 |
| Market Cap | 392.2 Mil. |
| Shares Out. | 363.2 Mil. |
| Earnings Date | Jul 31, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
